Skip to content
Screener

Emergent Biosolutions EBS Total Cost of Revenue

Total Cost of Revenue at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$100.7M+69.6%
SIGA Technologies logo
SIGA TechnologiesSIGA
$17.56M-31.3%
AMP
Amphastar PharmaceuticalsAMPH
$90.43M+2.9%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$461.69M+5.3%
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
$22.09M
Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
$6.84M-2.1%

Segments

By segment

See full
MCM Products$51.9M+100%
Commercial Products$36.2M0.0%

Other financials

Income statement

See full
Revenue$234.3M+66.3%
Gross profit$137.2M+85.4%
Operating income-$125.1M-7,919%
Net income-$180.2M-1,402%
EPS (diluted)-$3.49-1,486%

Balance sheet

See full
Cash & equivalents$140.9M-48.0%
Total debt$588.2M-13.0%
Total equity$341.4M-36.3%
Total assets$1.1B-21.2%

Cash flow

See full
Operating cash flow$56.1M-47.3%
CapEx$2.1M-27.6%
Free cash flow$54.0M-47.8%

Valuation

See full
Market cap$248.16M-43.0%
Enterprise value$695.46M-17.3%
P/S0.3×-0.2×

Profitability

See full
Gross margin55.9%+2.4pp
Operating margin15%+10.3pp
Net margin9.6%+5.8pp
FCF margin11.9%

Returns & leverage

See full
Return on equity13.9%+8.1pp
Debt / equity1.7×+0.5×
Current ratio5.4×-0.2×

Where this comes from

Reported directly by Emergent Biosolutions in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The source filing: Emergent Biosolutions’s 10-Q, filed August 6, 2026.

Filed
Aug 5, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001367644-26-000082
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Contracts and grants7.510.613.923.7
Total revenues234.3140.9390.4363.1
Operating expenses:
Cost of product and services sales, net (1)97.166.9169.1155.4
Research and development9.212.519.727.6
Selling, general and administrative44.643.791.296.1
Amortization of intangible assets17.216.233.732.5
Impairment of long-lived assets191.3191.3

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Emergent Biosolutions's total cost of revenue?
Emergent Biosolutions (EBS) reported total cost of revenue of $97.1M in Q2 2026.
How has Emergent Biosolutions's total cost of revenue changed year-over-year?
Emergent Biosolutions's total cost of revenue increased by 45.1% year-over-year, from $66.9M to $97.1M.
What is the long-term trend for Emergent Biosolutions's total cost of revenue?
Over 3 years (2022 to 2025), Emergent Biosolutions's total cost of revenue has grown at a -22.2% compound annual growth rate (CAGR), from $693.4M to $326.2M.
What does total cost of revenue mean?
The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.

Ask your AI about Emergent Biosolutions's total cost of revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude